Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects

Summary

This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.

Timeline

Start

2015-12

Primary completion

2018-10

Completion

2018-10

Publications

• Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, Senn JJ, Smith M, Almarsson Ӧ, Pujar HS, Laska ME, Thompson J, Zaks T, Ciaramella G. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019 May 31;37(25):3326-3334. doi: 10.1016/j.vaccine.2019.04.074. Epub 2019 May 10.

Drugs

Indications